Search results
It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.
New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.
jCyte have released additional preclinical data regarding jCell
We recently received an update on the latest research into Charles Bonnet Syndrome from Dr Jasleen Jolly as part of a Retina UK podcast about visual hallucinations.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
